Project Grant R35GM161485
- Federal Grant Award Summary The Ohio State University Office of Sponsored Programs received a $249,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on August 22, 2025, with a completion date of July 31, 2028. This grant funds fundamental research investigating the role of RNase L (ribonuclease L) host messenger RNA (mRNA) cleavage in viral infections, specifically examining how...
- Federal Project Grant Award Summary The Ohio State University received a $2,130,924 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2029. This award supports fundamental research into developmental regulation of oscillatory gene expression, specifically investigating the segmentation clock mechanism that controls somitogenesis—the...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Ohio State University $410,893 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support a research project titled "Genomics-Accelerated Discovery and Biosynthesis of Phosphonic Acid Natural Products." The award, with a completion date of December 31, 2030, funds fundamental research to discover and characterize novel microbial...
- Federal Grant Award Summary The Ohio State University received a $441,570 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026 through April 30, 2031. The award funds fundamental research to advance understanding of actin cytoskeleton organization and function, with particular focus on human plastins—versatile actin-binding proteins that organize actin filaments into...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Ohio State University $498,000 under the Biomedical Research and Research Training program (CFDA 93.859) for a three-year project grant beginning September 1, 2025, and concluding August 31, 2028. The research addresses fundamental gaps in understanding how protein synthesis is regulated during cell growth and division, with specific focus on the molecular mechanisms controlling...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Ohio State University $433,125 under the Biomedical Research and Research Training program (CFDA 93.859) to support research investigating the molecular consequences of microtubule bending in living cells. The five-year project, commencing August 1, 2025 and concluding June 30, 2030, will develop innovative molecular tools and techniques to manipulate and study cellular microtubule behavior...
- Federal Grant Award Summary The Ohio State University received a $416,726 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 11, 2025, with a completion date of August 31, 2030. The award supports the development of mass spectrometry-based technologies to enable chemical and proteomic analysis of organoids—three-dimensional cell cultures derived directly from human or...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Ohio State University a Project Grant totaling $375,898 under the Biomedical Research and Research Training program (CFDA 93.859) on March 10, 2026, with a completion date of February 28, 2031. This five-year award supports fundamental research investigating oligosaccharide cross-feeding and competition in microbial communities, specifically examining how human gut bacteria produce modified...
- The Ohio State University was awarded a $299,999 Project Grant from the National Science Foundation under the Biological Sciences federal grant program (CFDA 47.074) for work on "EAGER: IIBR INFORMATICS: A REINFORCED IMPUTATION FRAMEWORK FOR ACCURATE GENE EXPRESSION RECOVERY FROM SINGLE-CELL RNA-SEQ DATA." This two-year award beginning March 1, 2021 will support the development of a new computational framework to more accurately recover gene expression profiles from single-cell RNA...
- The National Science Foundation (NSF) awarded a $759,948 Project Grant under the Biological Sciences (CFDA 47.074) program to The Ohio State University. The funding will support a 3-year research project focused on characterizing the biogenesis and degradation of piRNAs (PIWI-interacting RNAs) in the model organism C. elegans. Key objectives include examining how piRNA production is regulated at the transcriptional level, investigating an unconventional cap-binding protein involved in processing...
The Ohio State University received a $419,674 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026 through January 31, 2031. This award supports fundamental research investigating the structure and mechanism of gene regulation by small noncoding ribonucleic acids (RNAs), specifically focusing on tiny guide RNAs (tyRNAs) and their interaction with human Argonaute proteins (AGOs). The research addresses critical knowledge gaps regarding how cleavage-inducing tyRNAs (cityRNAs) recognize and silence target messenger RNAs (mRNAs), the molecular mechanisms underlying poly(A)-specific ribonuclease (PARN) processing activities, and the distinct roles that the four human AGO proteins play in gene regulation beyond conventional silencing pathways. The project encompasses five key research objectives designed to elucidate tyRNA biogenesis pathways, structural characterization of AGO-tyRNA complexes, and the functional mechanisms by which these complexes regulate gene expression. Research activities will be conducted at The Ohio State University's Columbus, Ohio facility and are anticipated to generate foundational scientific knowledge that advances understanding of RNA-mediated gene silencing, potentially establishing the basis for future therapeutic applications in disease diagnosis and treatment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $419.7k | 4/28/26 |